scholarly journals Comparison of Breast Cancer Mortality in Five Countries: France, Italy, Japan, the UK and the USA from the WHO Mortality Database (1960–2000)

2005 ◽  
Vol 35 (12) ◽  
pp. 758-759 ◽  
Author(s):  
Toshihiko Kawamura ◽  
Tomotaka Sobue
2011 ◽  
Vol 7 (6) ◽  
pp. 631-633 ◽  
Author(s):  
André LM Verbeek

Evaluation of: Tabár L, Vitak B, Chen TH et al. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260(3), 658–663 (2011). In the 1980s, the periodic invitation of women aged 40–69 years for mammographic screening in the Swedish Two-County Trial showed a strong 30% reduction in breast cancer mortality. The result of 2–3-yearly mammographic examinations has persisted throughout the long follow-up of three decades. Through the richness of the collected and verified data, the trial has also demonstrated a substantial and absolute reduction in mortality risk. For each 414 women screened for 7 years (approximately four screening examinations), one breast cancer death was prevented. Transferring these outcomes to, for example, the national program of the UK, for every 1000 women aged 47–73 years attending the 3-yearly screenings (nine screening examinations) at least five to seven breast cancer deaths would be prevented. In recent follow-up papers by the Swedish trial group, the major human cost of screening (false-positive outcome, occurrence of interval cancer, overdiagnosis and radiation exposure) were judged to be in balance with the accurately demonstrated mortality benefit.


2015 ◽  
Vol 25 (3) ◽  
pp. 455-462 ◽  
Author(s):  
Nathalie J. Massat ◽  
Amanda Dibden ◽  
Dharmishta Parmar ◽  
Jack Cuzick ◽  
Peter D. Sasieni ◽  
...  

2018 ◽  
Vol 38 (1_suppl) ◽  
pp. 140S-150S ◽  
Author(s):  
Jeroen J. van den Broek ◽  
Nicolien T. van Ravesteyn ◽  
Jeanne S. Mandelblatt ◽  
Hui Huang ◽  
Mehmet Ali Ergun ◽  
...  

Background. The UK Age trial compared annual mammography screening of women ages 40 to 49 years with no screening and found a statistically significant breast cancer mortality reduction at the 10-year follow-up but not at the 17-year follow-up. The objective of this study was to compare the observed Age trial results with the Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer model predicted results. Methods. Five established CISNET breast cancer models used data on population demographics, screening attendance, and mammography performance from the Age trial together with extant natural history parameters to project breast cancer incidence and mortality in the control and intervention arm of the trial. Results. The models closely reproduced the effect of annual screening from ages 40 to 49 years on breast cancer incidence. Restricted to breast cancer deaths originating from cancers diagnosed during the intervention phase, the models estimated an average 15% (range across models, 13% to 17%) breast cancer mortality reduction at the 10-year follow-up compared with 25% (95% CI, 3% to 42%) observed in the trial. At the 17-year follow-up, the models predicted 13% (range, 10% to 17%) reduction in breast cancer mortality compared with the non-significant 12% (95% CI, -4% to 26%) in the trial. Conclusions. The models underestimated the effect of screening on breast cancer mortality at the 10-year follow-up. Overall, the models captured the observed long-term effect of screening from age 40 to 49 years on breast cancer incidence and mortality in the UK Age trial, suggesting that the model structures, input parameters, and assumptions about breast cancer natural history are reasonable for estimating the impact of screening on mortality in this age group.


Sign in / Sign up

Export Citation Format

Share Document